A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab
Authors
Keywords
-
Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 27, Issue 7, Pages 1465-1475
Publisher
Informa Healthcare
Online
2011-05-31
DOI
10.1185/03007995.2011.585394
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
- (2010) Yasuo Tano et al. ACTA OPHTHALMOLOGICA
- Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration
- (2010) Lesley H. Curtis ARCHIVES OF OPHTHALMOLOGY
- HIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
- (2010) Malik Y Kahook et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
- (2009) Manju L. Subramanian et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data
- (2009) Joseph S. Ross ARCHIVES OF INTERNAL MEDICINE
- Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy
- (2009) Neil M. Bressler ARCHIVES OF OPHTHALMOLOGY
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
- (2009) P Mitchell et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study
- (2009) M. J. Potter et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Clinical safety of ranibizumab in age-related macular degeneration
- (2009) Ursula Schmidt-Erfurth Expert Opinion On Drug Safety
- Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results
- (2009) S Sacu et al. EYE
- A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
- (2009) Christine Schmucker et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
- (2009) David S. Boyer et al. OPHTHALMOLOGY
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results
- (2008) Andrew N. Antoszyk et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
- (2008) G. Weigert et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Treatment of macular degeneration - controversy and hope
- (2008) S. J. McGimpsey et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Age-related macular degeneration and mortality from cardiovascular disease or stroke
- (2008) J S L Tan et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Age-Related Macular Degeneration
- (2008) Rama D. Jager et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More